http://www.aktiencheck.de aktiencheck.de aktiencheck.de Wed, 03 Jun 2026 19:58:03 +0200 2 http://www.aktiencheck.de/forum/VITROLIFE_AB_SK_02_WKN_A2JLT3-A2JLT3-t559374 http://www.aktiencheck.de/forum/VITROLIFE_AB_SK_02_WKN_A2JLT3-A2JLT3-t559374 Q4 und Gesamtjahr, Fourth quarter and full year report, 2023: Continued growth with margin expansionshttps://view.news.eu.nasdaq.com/view?id=baf94a4ff43136474522b6c256cec6c18&lang=en&src=microFourth quarter Sales of SEK 904 (855) million, an increase of 6%. In local currencies the growth was 5%. Sales, in local currencies increased by 16% in APAC and 6% in EMEA, while sales in Americas decreased by 5%. Sales in local currencies increased by 1% in Consumables and 31% in Technologies, while sales in Genetic Services decreased by 2%. Gross margin increased to 56.9% (54.2). Operating income before depreciation and amortisation (EBITDA) was SEK 294 (273) million, giving an EBITDA margin of 32.5% (31.9). Operating cash flow increased to SEK 171 million (166). An impairment charge of SEK 4,300 million is reported as other operating expenses. Net income was SEK -4,179 (73) million, resulting in earnings per share of SEK -30.86 (0.55). Excluding the impairment charge, net income incre [<a href="http://www.aktiencheck.de/forum/VITROLIFE_AB_SK_02_WKN_A2JLT3-A2JLT3-t559374">mehr</a>]